Kairos Pharma, Ltd. (KAPA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kairos Pharma, Ltd., a Delaware corporation and emerging growth company, on October 4, 2024, reporting events occurring on October 1, 2024. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbol "KAPA".
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a new contractual agreement.
Material Changes and Agreements
On October 1, 2024, the Company entered into a Material Definitive Agreement (Consulting Agreement) with Cross Current Capital LLC and Alan Masley (the "Advisor"). Key terms include:
- Services: Financial and business consulting, including valuation analysis, marketing materials, investor relations, M&A canvassing, and capital markets advisory.
- Compensation:
- Cash payment of $200,000 to Cross Current.
- Issuance of restricted common stock valued at $500,000 to the Advisor under the 2023 Equity Incentive Plan.
- Reimbursement of pre-approved reasonable expenses.
- Vesting: The stock shares shall vest at the end of six months after issuance.
- Term: 24 months, with an option to extend for an additional 12 months upon mutual written consent.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or specific risk factors beyond the standard disclaimer that the summary is qualified by reference to the full agreement text. The agreement is intended to assist the company in financing, business opportunities, and investor marketing.
Investor Verification Checklist
- Verify the dilution impact of the $500,000 stock issuance on existing shareholders.
- Confirm the vesting schedule details and any performance conditions attached to the Advisor's shares.
- Review the full text of Exhibit 10.1 for specific termination clauses and expense caps.
- Assess the Company's current cash position to ensure it can meet the immediate $200,000 cash obligation.